

Serial No. 10/520,552

RECEIVED
CENTRAL FAX CENTER
Atty. Docket No. LeA 36 079
OCT 31 2006

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 1-4, 6-8, and 14 are pending in this application. Claims 9 and 10 have been cancelled and claims 1-4 and 6-8 have been amended. These claim amendments are made to clarify the subject matter therein. Therefore, these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Rejection Under 35 U.S.C. § 112, second paragraph

The Examiner rejected claims 1-4, 6-10, and 14 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the Applicant regards as the invention (Paper No. 20060621, pages 2-3). Applicants respectfully traverse this rejection.

Claims 9 and 10 have been cancelled.

The Examiner stated that the recitation of "and their salts, solvates or solvates of the salts thereof" renders claims 1-4, 6-10, and 14 indefinite as it is not clear whether these claims are compound claim or composition claim with the said limitations.

The claims have been amended as suggested by the Examiner.

The Examiner stated that the recitation of "compounds" in claim 4 at various places renders claim 4 and 14 indefinite as it is not clear whether these claims are for a process of making a compound or a composition with various compounds.

The claim has been amended as suggested by the Examiner.

The Examiner stated that the recitation of "at least one compound" in claim 6 renders this claim indefinite as it is not clear whether these claims are simple composition claim with compound of claim 1 as one active ingredient or a complex composition with the limitation that it needs one compound of claim 1 and other active ingredients.

The claim has been amended as suggested by the Examiner.

It is thus submitted that the claims 1-4, 6-8, and 14 meet the requirements of 35 USC § 112, second paragraph, and reconsideration and withdrawal of the present rejection is respectfully requested.

Serial No. 10/520,552

Atty. Docket No. LeA 36 079

Rejection Under 35 U.S.C. § 112, first paragraph

The Examiner rejected claims 1-4, 6-10, and 14 under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for making salts of the claimed compounds, does not reasonably provide enablement for making solvates or solvates of the salts of the claimed compounds (Paper No. 20060621, pages 3-7). Applicants respectfully traverse this rejection.

Claims 9 and 10 have been cancelled.

To expedite prosecution, claims 1-4 have been amended, and no longer recite "solvates or solvates of the salts."

The Examiner rejected claims 7-10 under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for treating Parkinson's disease and schizophrenia, does not reasonably provide enablement for treating any or all neurodegenerative diseases, psychiatric disorders, any or all cancer or prophylaxis of any or all neurodegenerative diseases, psychiatric disorders, any or all cancer generically embraced in claims 7, 8 or specifically embraced in claims 9 and 10.

Claims 9 and 10 have been cancelled.

To expedite prosecution, claims 7 and 8 have been amended, and no longer recite "and/or prophylaxis of neurodegenerative disorders" and "and/or prophylaxis of cancer and psychiatric disorders."

It is thus submitted that the claims meet the requirements of 35 USC § 112, first paragraph, and reconsideration and withdrawal of the present rejection is respectfully requested.

Serial No. 10/520,552


Atty. Docket No. LeA 36 079

CONCLUSION

For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, reconsideration and withdrawal of the present rejections and objections, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Balasubramanian is invited to contact the undersigned counsel.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigncd's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,



Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Date: October 31, 2006

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459